3728 Jinke Rd, Bldg 1, West Wing, Shanghai, China
info@tyligand.com
Tyligand Bioscience to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Shanghai, Jan 14th, 2025 - Tyligand Bioscience, a clinical-stage biotechnology company dedicated to developing innovative therapeutics against drug resistant tumors, today announced that Tony Zhang, Ph.D., the company’s Chief Executive Officer and Co-founder, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, Jan 16th, 2025 at 1:15 p.m. PST in San Francisco.
To access the live webcast of the presentation, please visit the “Corporate News” page of Tyligand Bioscience’s website at https://en.tyligand.com.cn/tyligand-news/news-release. Additionally, a replay will be available for at least 14 days following the conference.
Founded in 2018, Tyligand Bioscience is a clinical stage biotech focusing on the discovery and development of transformative therapies for cancer. In addition to the KRAS G12D program, the company has several molecules in development, including TSN084, a Type II multi-kinase inhibitor; TSN222, a first in kind dual acting tumor immune agonist (DATIA®), and a platform for antibody drug conjugates (ADCs) featuring proprietary linkers and novel payloads.
For more information about Tyligand Bioscience, please visit www.tyligand.com